Log In
Print
BCIQ
Print
Print this Print this
 

GC33, RG7686

Also known as: RO5137382

  Manage Alerts
Collapse Summary General Information
Company Chugai Pharmaceutical Co. Ltd.
DescriptionHumanized anti-glypican 3 (GPC3) mAb
Molecular Target Glypican 3 (GPC3)
Mechanism of Action 
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationLiver cancer
Indication DetailsTreat hepatocellular cancer (HCC); Treat metastatic liver cancer
Regulatory Designation

Partner

Roche


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today